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A B S T R A C T
Autoradiography (ARG) is a high-resolution imaging method for localization of radiolabeled biomarkers in ex
vivo specimen. ARG using 2-deoxy-D-glucose (2-DG) method is used in to study drug actions on brain functional
activity, as it provides results comparable to clinically used functional positron-emission tomography (PET). The
requirement of slow analog detection methods and emerging advances in small animal PET imaging have,
however, reduced the interest in ARG. In contrast to ARG, experimental animals need to be restrained or se-
dated/anesthetized for PET imaging, which strongly influence functional activity and thus complicate the in-
terpretation of the results. Digital direct particle-counting ARG systems have gained attraction during the last
decade to overcome the caveats of conventional ARG methods. Here we demonstrate that the well-established 2-
DG imaging method can be adapted into use with contemporary digital detectors. This method readily and
rapidly captures the characteristic effects of phencyclidine (5 mg/kg, i.p.), a dissociative agent targeting the
NMDAR (N-methyl-D-aspartate receptor), on regional glucose utilization in the adult mouse brain. Pretreatment
with antipsychotic drug clozapine (6 mg/kg, i.p.) essentially abolishes these effects of phencyclidine on brain
functional activity. Digital ARG produces viable data for the regional analysis of functional activity in a fraction
of time required for film development. These results support the use of digital ARG in preclinical drug research,
where high throughput and response linearity are preferred and use of sedation/anesthesia has to be avoided.
1. Introduction
Glucose is the predominant energy substrate of the brain under
normal conditions and is required for all neuronal functions (Sokoloff
et al., 1977). The correlation between glucose utilization and functional
activity of neurons has been determined to the extent that the glucose
consumed by a single action potential can be quantified (Sokoloff,
1999). Clinical symptoms of various psychiatric disorders, such as
schizophrenia (Mitelman et al., 2018; Cleghorn et al., 1989; Farkas
et al., 1984; Kishimoto et al., 1987), depression (Drevets et al., 1997,
1992; Biver et al., 1994; Baxter et al., 1989), and bipolar disorder
(Drevets et al., 1997; Hosokawa et al., 2009; Keener and Phillips, 2007;
Brooks and Vizueta, 2014) are reflected in distinctive patterns of altered
cerebral glucose utilization that can be restored using pharmacological
treatments (Buchsbaum et al., 1992; Bartlett et al., 1998; Wolkin et al.,
1996; De Crescenzo et al., 2017; Kang et al., 2012; Forlenza et al., 2014;
Little et al., 2005). In preclinical research, this enables the use of
functional imaging methodology to screen for potential drug candidates
by their ability to modulate disorder-related functional alterations.
The 2-deoxy-D-glucose (2-DG) method developed by Sokoloff et al.
(1977) measures the rates of energy metabolism in discrete brain re-
gions in both normal and altered states using the correlation between
glucose utilization and functional activity. In this method, radiolabeled
(usually 14C or 3H) glucose derivate 2-DG is systemically injected into
an animal, followed by an uptake period ranging generally from 5 to
45 min (Sokoloff et al., 1977; Duncan et al., 1989). During the uptake
period, the compound is transported and trapped inside cells in a
quantity directly relative to their ongoing metabolic (i.e. functional)
activity. When the brain is sectioned, the distribution of the radiolabel
can be detected ex vivo to form a spatial visualization of regional glu-
cose utilization during the uptake period. The 2-DG method was ori-
ginally developed to use with autoradiography (ARG), which is a sen-
sitive, high resolution nuclear imaging technique used to study
distribution of radiolabeled compounds. While the method has since
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been adapted for use in in vivo and clinical setting with 18F-labeled 2-
DG (FDG) and positron emission tomography (PET), ARG still enables
higher spatial resolution (Koba et al., 2011; Yang et al., 2016; d’Argy
and Sundwall, 2000; Solon, 2015; Schmidt and Smith, 2005; Barthe
et al., 2012), cheaper costs (Fine et al., 2014; Upham and Englert,
2003), and longer temporal window for imaging (Solon and Kraus,
2001). Due to ARG imaging being performed using dissected ex vivo
samples, it also does not require the use of anesthesia or physical re-
straint during imaging, both of which are known to strongly alter
functional brain activity and connectivity, glucose utilization, and
several other neurobiological measures (Ohata et al., 1981; Ori et al.,
1986; Herkenham, 1981; Kohtala et al., 2016; Theilmann et al., 2019;
Boretius et al., 2013; Hildebrandt et al., 2008; Momosaki et al., 2004;
Toyama et al., 2004; Eintrei et al., 1999; Lenz et al., 1998; Paasonen
et al., 2018; Antila et al., 2017). Thus, the small animal PET and other
small animal imaging methods often have significant confounding
factors interfering with research of treatments for central nervous
system (CNS) disorders.
There is an enormous need for new and more efficient tools in the
field of CNS drug development, where the amount of novel discoveries
has dwindled over the recent decades (Caraci et al., 2017; Preskorn,
2011). With the advances in direct particle-counting systems, the new
digital ARG devices have surpassed the conventional film and phosphor
screen-based ARG in linearity (Kelly and McCulloch, 1983; Lear, 1986;
Ott et al., 2000; Cabello et al., 2007), dynamic range (Upham and
Englert, 2003; Barthe et al., 1999, 2004), and sensitivity (Nicole Barthe
et al., 2012; Ott et al., 2000; Solon and Moyer, 2014), reducing the
acquisition times from months to just few hours. In this study, we as-
sessed the potential of using digital ARG with gas-based charged-par-
ticle imager as a screening method for preclinical research by quanti-
fying the ability of an antipsychotic drug clozapine in restoring the
functional alterations induced by phencyclidine (PCP), a psychotomi-
metic that acutely triggers behavioral and perceptual changes resem-
bling schizophrenia or psychosis (Javitt et al., 2012). The used PCP
model has been previously validated using conventional ARG (Duncan
et al., 1998, 2000; Duncan et al., 2003; Weissman et al., 1987), but the
long exposure times and the use of rats have reduced viability of the
method for cheap high-throughput screening, where short imaging
times and cheaper laboratory rodents would be preferred. Our aim was
to establish whether this type of imaging could be utilized for rapid
screening of functional effects produced by pharmacological agents.
2. Materials & methods
2.1. Animals
All animal experiments were carried out according to the National
Institute of Health (NIH) guidelines for the care and use of laboratory
animals and approved by National Animal Experiment Board of Finland
(License number ESAVI-2015-2269). A total of 15 healthy male C57BL/
6 J mice (Charles River Laboratories, Kisslegg, Germany), aged
7–8 weeks and weighing 23.5 (± 0.76) grams were used in the ex-
periment. Animals were group-housed (4 animals in a cage) in stainless
steel cages and kept on a controlled 12-h light/dark cycle at an ambient
temperature of 22 ± 1 °C with access to food and water available ad
libitum. Three hours prior to the experimental procedures, cages
housing the animals were moved to experiment room and the access to
food was suspended to ensure stable blood glucose level and adequate
radiolabel uptake. Experiments were conducted between 3 and 8 h after
light onset.
2.2. Drugs and administration
An aqueous solution of 3H-2-DG (2-[1,2-3H (N)]-deoxy-D-glucose,
20 Ci/mmol; PerkinElmer Inc., Boston, USA) was administered in a
volume of 100 μl via i.v. injection to tail vein. Phencyclidine (PCP; 1-(1-
Phenylcyclohexyl)piperidine hydrochloride; Tocris Bioscience, Bristol,
UK) was dissolved in sterile saline at a concentration of 1 mg/ml.
Clozapine (CLZ; Sigma-Aldrich Co. LLC, St. Louis, USA) was dissolved in
0.1 M hydrochloric acid, adjusted to pH 7 with 0.1 M sodium hydro-
xide, and then diluted to a concentration of 1.2 mg/ml with sterile
saline. Both PCP and CLZ injections were administered via i.p. injec-
tions in volume of 5 ml/kg, resulting in doses of 5 mg/kg and 6 mg/kg,
respectively. Vehicle (VEH), sterile 0.9% saline solution, was injected
i.p. in a same volume as the drugs.
The animals were divided to three treatment groups: 1) VEH+ PCP,
2) CLZ + PCP, and 3) VEH + VEH (n = 5 in all groups). At first, the
mice received i.p. injection of either CLZ or VEH and were transferred
back to their home cages. At 30 min after the first injection, either PCP
or VEH was administered and the mice were transferred to a temporary
empty cage. 15 min after the PCP or VEH injection the mice were re-
strained and received 100 μl of 3H-2-DG in a concentration of 375 μCi/
ml, or approximately 1.6 μCi/g body weight, via an intravenous in-
jection to tail vein. The animals were terminated after a glucose uptake
period of 15 min post-radiotracer injection. A schematic for experi-
mental timeline is presented in Fig. 1.
2.3. Sample processing
The animals were euthanized exactly 15 min after 3H-2-DG injection
using CO2 and a terminal blood sample was collected via cardiac
puncture. The blood samples were centrifuged (2000 g, 10 min, +4 °C)
and the resulting supernatant collected for analysis. The brains were
immediately dissected and flash frozen by immersing them in 2-me-
thylbutane (isopentane) pre-chilled on dry ice for under a minute
(Gonzales-Lima, 1992; Maker and Lehrer, 1971). No fixative was used
in order to ensure propagation of β-particles from the tissue to detector.
Dissected brains were then stored at −80 °C until moved to −20 °C the
day before sectioning. Twenty (20) μm thick coronal sections were thaw
mounted on a plain glass slides in a cryostat (Leica CM1950) at −14 °C
every 100 μm beginning approximately from bregma +3,55 mm and
ending approximately to bregma −7,55 mm, resulting in 112 coronal
sections of each brain.
2.4. The autoradiographic analysis of 3H-2-DG uptake
Autoradiographs were acquired using a gaseous scintillator-coupled
β-emission detecting charge-coupled device (CCD) camera, BetaImager
TRacer (Biospace Lab, Paris, France), using a 6-h acquisition time and a
full-field zoom setting (250 × 200 mm). 12 pre-chosen regions of in-
terest (ROI) were outlined using Paxinos' and Allen's mouse brain atlas
overlays in an image processing software M3 Vision (Biospace Lab,
Paris, France) (Lein et al., 2007; Paxinos and Franklin, 2012). Each ROI
was analyzed on 8–15 brain sections, depending on the size of the
structure. The regional functional activity was analyzed with a semi-
quantitative method (Vyazovskiy et al., 2004; Duncan and Stumpf,
1991), which allows the study of more time-limited effects of drugs
compared to the original method requiring 45-min radiolabel uptake
period and multiple blood samples. The detected rates of regional beta-
emission (cpm/mm2) were normalized to an internal control (corpus
callosum) to account for biological variation, and thus the data are
expressed as the ratio of cpm/mm2 of a ROI to that of corpus callosum.
Comparison of treatment effects to all regions and individual ROI of
Fig. 1. Study timeline for drug and radiolabel administration.
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treatment groups were performed using one-way analysis of variance
(ANOVA) followed by a Tukey's post-hoc test.
2.5. Plasma radioactivity analysis
A tritium concentration standard was prepared by creating a pro-
portional 12-step serial dilution with a dilution factor of 1:2, using
375 μCi/ml 3H-2-DG and rat plasma. A liquid scintillation counter
(MicroBeta2 Plate Counter, PerkinElmer) was used to measure the ac-
tivity (cpm) of all standard solutions and animal terminal plasma
samples. The plasma radioactivity (μCi/ml) content of each animal at
the time of termination was then calculated by fitting the measured
sample activity to the standard. The total circulating blood and plasma
volumes were estimated using literature (Diehl et al., 2001). The data




Experimenters followed behavioral responses of the animals after
treatment administration and documented the visual observations. The
mice displayed expected acute behavioral responses to the drug treat-
ments. Based on visual observations, PCP induced increased locomotor
activity and stereotypy (Chen et al., 1965; Chen et al., 1959). The sti-
mulating properties of PCP were also visually observed in the cardio-
vascular system (vasoconstriction of tail vein when injecting radiolabel,
increased heart and breathing rate). Mice injected with CLZ became
significantly sedated within five minutes from injection (Coward,
1992). With the current doses, the observed effects of CLZ completely
overwhelmed those of PCP in animals subjected to both treatments.
These responses to the drugs persisted until the termination of the an-
imals.
3.2. The autoradiographic analysis of 3H-2-DG uptake
Full-field autoradiographic acquisition using BetaImager TRacer
resulted in digital images with an initial pixel resolution of
1488 × 1190, which equal to a pixel size of 168 μm2 on a
250 mm × 200 mm field of view. Representative sections with anno-
tated ROIs (region-of-interests), shown as greyscale and heat map
images, are shown with their respective atlas overlays in Fig. 2.
PCP treatment induced pronounced alterations in the 2-DG uptake
pattern throughout the whole brain (Fig. 3). The increase in glucose
uptake was found to be neuroanatomically selective, with some regions
responding to PCP significantly more than others. Overall, when com-
paring the ROI median values of studied brain regions, the mice treated
with PCP had significantly higher regional functional activity in com-
parison to mice which received CLZ pretreatment or vehicle only
(p≤ 0,0001). The trend is also apparent when the individual ROI of the
treatment groups are compared (Fig. 4). The regional functional ac-
tivity of the PCP-treated animals without CLZ pretreatment was sig-
nificantly higher in comparison to control group in all the individual
measured ROI, except for cerebellum and inferior colliculus. CLZ pre-
treatment altered the functional activity of the PCP-injected mice in
majority of the ROI. CLZ pretreatment failed to restore the PCP-induced
increase in functional activity only in the amygdala.
3.3. Plasma analysis
Calculated mean radioactivity in the plasma at the time of termi-
nation was 0.227 (± 0.079) μCi, suggesting that only roughly 1% of
the original injected radiolabel dose had remained in the blood circu-
lation. Activity difference between VEH+ VEH and VEH+ PCP groups
was found non-significant, but the activity of CLZ + PCP group
surpassed that of other groups (p ≤ .01). The results of plasma analysis
are shown in Supplementary Fig. S1.
4. Discussion
While functional imaging using 2-DG method has been extensively
described using conventional (film) ARG, the present study is the first
(to our knowledge) to demonstrate functional imaging using newer
direct particle-counting system. Digital ARG enabled the use of low
activity radiolabel tritium and acquisition time of only 6 h to produce
enough data for quantification. While piloting the method, we exposed
additional sections on phosphor image plates (IP) for 13 days and
scanned them using FLA scanner on 10 μm resolution (Supplementary
Fig. S2). Due to the low specific activity of 3H-2-DG, the IP detection
produced quantification-impairing amount of background noise and
low contrast between brain regions, demonstrating the superior sensi-
tivity and dynamic range of the digital detector.
Functional imaging using ARG is comparable to human PET ima-
ging, widely used in clinical setting, and therefore possesses high
translational value. The method described in this study has the same
underlying rationale as the semi-quantitative functional auto-
radiography method, making the acquired results comparable with
previous literature based on traditional analog autoradiography (G. E.
Duncan et al., 1993; Duncan et al., 1999; Miyamoto et al., 2000). In-
deed, the selective metabolic activation seen in the present study bears
resemblance to NMDAR antagonist-induced alterations seen in humans
and in animal models (Vollenweider et al., 1997a; Vollenweider et al.,
1997b; Långsjö et al., 2004; Gao et al., 1993). We selected the dose of
PCP based on the report by Xue-Min Gao et al. (1993) who also de-
scribed prominent metabolic effects and behavioral phenotypes re-
sembling the positive symptoms of schizophrenia. It should be noted
that with this dose range PCP triggers also non-NMDA receptor-medi-
ated effects, namely dopaminergic actions (D. C. Javitt and Zukin,
1991). However, the observed patterns in metabolic activation more
closely mirrored those produced by other NMDA receptor antagonists,
rather than pure dopaminergic psychoactive drugs such as ampheta-
mine (Miyamoto et al., 2000).
The plasma radioactivity analysis was used to control that all ani-
mals were properly injected with radiolabel. CLZ administration (and
resulting sedation) was reflected as higher remaining radiolabel in the
circulation compared to other groups. In addition, plasma analysis re-
vealed one outlier in the VEH + PCP group, where the animal had
slightly delayed radiolabel administration time, resulting in higher
amount of radiolabel remaining in circulation at time of termination.
However, as the quantification of ROI glucose utilization was normal-
ized to the internal standard of each animal, this did not impact the
overall analysis of functional activity.
High sensitivity of the direct particle-counting systems enables de-
tection of even minute amounts of radionuclide present in the samples.
This establishes the two greatest benefits of the method, reduction in
time it takes to conduct functional imaging studies and the possibility to
use low-energy isotopes. Decreasing the acquisition time from months
or weeks to only hours enables high throughput and considerably
streamlines experiments utilizing functional autoradiography, thus
lowering costs and speeding up research. Additionally, the digital ac-
quisition can be followed in real time, while the conventional methods
require estimation and piloting of the exposure time based on used
amount of radionuclide. Use of low-energy radiolabels brings forth
further practical benefits. In comparison to 18F used in FDG PET, iso-
topes such as 3H or 14C are considerably cheaper and enable working
under consignment limits issued by European Union in Council
Directive 2013/59/Euratom (2013) and United States Code of Federal
Regulations 49 CFR § 173.436 (2011). These benefits make digital ARG
fast, cheap, and safe method for functional imaging suitable for
screening treatment effects on brain activity. By enabling rapid as-
sessment of functional effect of treatments, digital detectors possess
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significant advantages in academic and industrial use over conventional
autoradiography.
As a drawback, the high sensitivity contributes to the visually noisy
appearance of the autoradiographs as seen in Fig. 2. Therefore, the
visual appearance of the autoradiographs acquired using direct particle-
counting systems is clearly inferior to conventional film auto-
radiographs. However, it should be noted that the visual noise does not
affect image quantification, as the quantification is not done using
image itself, but accurate numeric temporal and spatial coordinates of
each detected β-particle emission stored by the system. Compared to
conventional autoradiography, there is also no loss of information in
quantification resulting from the analog-to-digital conversion of the
scanned film or phosphor plates. Nevertheless, the current method has
considerably lower spatial resolution in comparison to conventional
autoradiography, where even cellular resolution can be achieved.
Therefore, if the goal is to acquire more accurate spatial localization
data of functional activation (e.g. activation of individual nuclei), al-
ternative digital detector types or conventional autoradiography should
be considered. Basic comparison of conventional autoradiography, di-
gital autoradiography, and small animal PET imaging is provided in
Table 1. The spatial resolution achieved using the current gas-based
charged-particle imager was found to be sufficient for detecting the
functional activity in discrete regions of mouse brain, enabling rapid
screening process. It can also be argued that in pharmacological ex-
periments, response linearity for dose-effect quantification should be
prioritized over spatial resolution, especially if the goal of the experi-
ment is to quickly screen different compounds.
Obvious limitation of the method is that it only allows determina-
tion of glucose utilization at one time point. For FDG PET, newer
Fig. 2. Digital autoradiography A) An example of qualitative results acquired from control group with BetaImager TRacer using 3H-labeled 2-deoxy-D-glucose as a
tracer. The acquisition was performed for 6 h on a full-field zoom setting (250 × 200 mm). The images proceed vertically from the anterior to posterior part of the
brain, with the coordinates shown in the upper left corner of each row. Leftmost column: acquisition data shown as monochrome images resembling film auto-
radiograph. Center column: the previous acquisition data displayed as a gradient heat map from cold to warm colors, with cold colors representing less and warm
colors more cpm/mm2 respectively. Right column: the heat maps are overlaid with their respective anatomical maps from Paxinos' mouse brain atlas. B)
Representative sections of most relevant regions of interest from each treatment group displaying treatment-induced effect in regional glucose utilization. As seen in
the CLZ + PCP group, overall glucose utilization is lower due to sedative effects of CLZ.
Cg: Cingulate cortex; NAc: Nucleus accumbens; Pir: Piriform cortex; CPu: Caudate putamen; SC: Primary somatosensory cortex; TH: Thalamic nuclei; HTh:
Hypothalamic nuclei; RSP: Retrosplenial cortex; HC: Hippocampus; AM: Amygdala; MB: Mammillary body (part of hypothalamic nuclei); IC: Inferior colliculus; CB:
Cerebellum; PCP: Phencyclidine; CLZ: Clozapine.
Fig. 3. Comparison of the functional activity in all analyzed regions of interest
(ROI) of the three treatment groups. Data are expressed as the ratio of activity
(cpm/mm2) in a region of interest (ROI) to that of corpus callosum. Each data
point signifies the mean value of all animals in each ROI. In comparison to the
other treatment groups, VEH + PCP group has significantly higher global
functional activity in the measured ROI. Abbreviations: VEH: vehicle; PCP:
phencyclidine (5 mg/kg); CLZ: clozapine (6 mg/kg).
***: significant difference when compared to VEH + VEH group (p < .0001);
†††: significant difference when compared to CLZ + PCP group (p < .0001).
O. Alitalo, et al. Progress in Neuropsychopharmacology & Biological Psychiatry 100 (2020) 109887
4
approaches have been developed to enable measurement of dynamic
alterations in brain activity during FDG PET imaging in humans (Villien
et al., 2014; Hahn et al., 2016; Rischka et al., 2018). Alternative me-
tabolism-reflecting radiolabels, such as 15O, can also be utilized to as-
sess dynamic changes of limited temporal nature (Sheppard et al., 1983;
Carter et al., 1997). Longitudinal studies with 15O have been demon-
strated feasible in small animals (Wehrl et al., 2014). However, as
discussed in this manuscript, most preclinical methods utilizing PET
detection are impeded by the requirement of anesthesia or restraint.
While some novel methodology have been utilized for functional PET
and SPECT imaging of freely moving animals, these methods have
lower spatial resolution and lack the decades of validation behind
functional ARG (Baba et al., 2013; Spangler-Bickell et al., 2016).
As the goal of this research was methodological development, only
male mice were used in order to increase the comparability to previous
research. Significant majority of previous research into PCP-induced
hyperfrontality has utilized male rodents (Kargieman et al., 2007;
Duncan et al., 1998; Gao et al., 1993; Weissman et al., 1987). However,
female rodents have been shown to metabolize PCP slower in com-
parison to males (Shelnutt et al., 1999). While more research is required
to validate the used pharmacological model in both sexes, this factor
does not affect the primary focus of this study, which was development
of novel methodology for digital autoradiography.
5. Conclusion
The method described in this study provides a compelling alter-
native to small animal PET and SPECT imaging, as it can be performed
Fig. 4. Regional functional activity of the animals treated with vehicle only (VEH + VEH, n = 5), vehicle and 5 mg/kg of phencyclidine (VEH + PCP, n = 5), or
6 mg/kg of clozapine and 5 mg/kg of phencyclidine (CLZ + PCP, n = 5). Data are mean ± SD, and expressed as the ratio of radioactivity (cpm/mm2) in the region
of interest (ROI) to that of corpus callosum, with each data point shown representing a mean regional activity measured from one brain.
*, **, or ***: significant difference when compared to VEH + VEH group (One-way ANOVA with Tukey's post-hoc test p-value ≤.05, 0.01, or 0.001, respectively); †,
††, †††: significant difference when compared to CLZ + PCP group (p ≤ .05, 0.01, 0.001 respectively).
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on samples collected from freely moving animals. As discussed, the use
of anesthesia or restraining of the animal during imaging are both
major confounding factors impairing the translational value of results
acquired with PET and SPECT imaging. Thus, ARG remains as the
cheapest, highest resolution, and most clinically translatable functional
imaging method for preclinical studies, especially in CNS research.
Overall, our results support the use of digital autoradiography-based
functional imaging for screening the effects of drugs on brain activity.
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